Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Buy
78
INBS Quote, Financials, Valuation and Earnings
Last price:
$11.68
Seasonality move
:
-17.76%
Day range:
$9.90 - $12.75
52-week range:
$4.03 - $27.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
21.27x
P/B ratio:
2.84x
Volume:
1.8M
Avg. volume:
4.4M
1-year change:
-26.71%
Market cap:
$10.3M
Revenue:
$3.1M
EPS (TTM):
-$1.71
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
INBS
Intelligent Bio Solutions, Inc.
|
$1.4M | -- | 160.36% | -- | -- |
|
ADGM
Adagio Medical Holdings, Inc.
|
-- | -$0.31 | -100% | -91.79% | $4.00 |
|
LAB
Standard BioTools, Inc.
|
$18.5M | -$0.03 | -60.4% | -72.53% | $1.65 |
|
LNSR
LENSAR, Inc.
|
$20.5M | -$0.09 | 30.98% | -90.51% | $15.00 |
|
MOVE
Movano, Inc.
|
$3.4M | -$7.10 | 76.06% | -41.21% | $30.00 |
|
NPCE
NeuroPace, Inc.
|
$24.4M | -$0.19 | 13.81% | -5.76% | $19.25 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
INBS
Intelligent Bio Solutions, Inc.
|
$10.70 | -- | $10.3M | -- | $0.00 | 0% | 21.27x |
|
ADGM
Adagio Medical Holdings, Inc.
|
$0.99 | $4.00 | $21M | 218.00x | $0.00 | 0% | 110.91x |
|
LAB
Standard BioTools, Inc.
|
$1.27 | $1.65 | $488.4M | -- | $0.00 | 0% | 3.74x |
|
LNSR
LENSAR, Inc.
|
$11.45 | $15.00 | $136.8M | -- | $0.00 | 0% | 2.29x |
|
MOVE
Movano, Inc.
|
$7.78 | $30.00 | $6.5M | -- | $0.00 | 0% | 11.77x |
|
NPCE
NeuroPace, Inc.
|
$16.39 | $19.25 | $545.9M | -- | $0.00 | 0% | 5.50x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
INBS
Intelligent Bio Solutions, Inc.
|
35.02% | 2.237 | 21.48% | 0.47x |
|
ADGM
Adagio Medical Holdings, Inc.
|
106.35% | 0.022 | 73.62% | 0.48x |
|
LAB
Standard BioTools, Inc.
|
6.41% | 0.680 | 5.49% | 1.93x |
|
LNSR
LENSAR, Inc.
|
-31.16% | -0.941 | 1.79% | 0.65x |
|
MOVE
Movano, Inc.
|
212.35% | 3.110 | 67.05% | 0.29x |
|
NPCE
NeuroPace, Inc.
|
79.36% | 0.372 | 20.74% | 3.82x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
INBS
Intelligent Bio Solutions, Inc.
|
$214.9K | -$2.9M | -213.68% | -255.54% | -263.64% | -$2.9M |
|
ADGM
Adagio Medical Holdings, Inc.
|
-$531K | -$5.7M | -193.23% | -340.49% | -- | -$3.5M |
|
LAB
Standard BioTools, Inc.
|
$9.5M | -$23.5M | -22.34% | -24.44% | -120.02% | -$23.1M |
|
LNSR
LENSAR, Inc.
|
$5.8M | -$7.6M | -684.94% | -1013.45% | -52.95% | -$3.5M |
|
MOVE
Movano, Inc.
|
-$200K | -$2.6M | -337.24% | -410.28% | -3238.75% | -$1.6M |
|
NPCE
NeuroPace, Inc.
|
$21.2M | -$2.6M | -27.09% | -149.8% | -9.51% | -$2M |
Intelligent Bio Solutions, Inc. vs. Competitors
-
Which has Higher Returns INBS or ADGM?
Adagio Medical Holdings, Inc. has a net margin of -269.38% compared to Intelligent Bio Solutions, Inc.'s net margin of --. Intelligent Bio Solutions, Inc.'s return on equity of -255.54% beat Adagio Medical Holdings, Inc.'s return on equity of -340.49%.
Company Gross Margin Earnings Per Share Invested Capital INBSIntelligent Bio Solutions, Inc.19.33% -$0.35 $5.4M ADGMAdagio Medical Holdings, Inc.-- -$0.66 $20.7M -
What do Analysts Say About INBS or ADGM?
Intelligent Bio Solutions, Inc. has a consensus price target of --, signalling upside risk potential of 1021.5%. On the other hand Adagio Medical Holdings, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 303.67%. Given that Intelligent Bio Solutions, Inc. has higher upside potential than Adagio Medical Holdings, Inc., analysts believe Intelligent Bio Solutions, Inc. is more attractive than Adagio Medical Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INBSIntelligent Bio Solutions, Inc.0 0 0 ADGMAdagio Medical Holdings, Inc.1 0 0 -
Is INBS or ADGM More Risky?
Intelligent Bio Solutions, Inc. has a beta of 4.455, which suggesting that the stock is 345.491% more volatile than S&P 500. In comparison Adagio Medical Holdings, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock INBS or ADGM?
Intelligent Bio Solutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adagio Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intelligent Bio Solutions, Inc. pays -- of its earnings as a dividend. Adagio Medical Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INBS or ADGM?
Intelligent Bio Solutions, Inc. quarterly revenues are $1.1M, which are larger than Adagio Medical Holdings, Inc. quarterly revenues of --. Intelligent Bio Solutions, Inc.'s net income of -$3M is higher than Adagio Medical Holdings, Inc.'s net income of -$10.1M. Notably, Intelligent Bio Solutions, Inc.'s price-to-earnings ratio is -- while Adagio Medical Holdings, Inc.'s PE ratio is 218.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intelligent Bio Solutions, Inc. is 21.27x versus 110.91x for Adagio Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INBSIntelligent Bio Solutions, Inc.21.27x -- $1.1M -$3M ADGMAdagio Medical Holdings, Inc.110.91x 218.00x -- -$10.1M
-
Which has Higher Returns INBS or LAB?
Standard BioTools, Inc. has a net margin of -269.38% compared to Intelligent Bio Solutions, Inc.'s net margin of -162.05%. Intelligent Bio Solutions, Inc.'s return on equity of -255.54% beat Standard BioTools, Inc.'s return on equity of -24.44%.
Company Gross Margin Earnings Per Share Invested Capital INBSIntelligent Bio Solutions, Inc.19.33% -$0.35 $5.4M LABStandard BioTools, Inc.48.51% -$0.09 $427M -
What do Analysts Say About INBS or LAB?
Intelligent Bio Solutions, Inc. has a consensus price target of --, signalling upside risk potential of 1021.5%. On the other hand Standard BioTools, Inc. has an analysts' consensus of $1.65 which suggests that it could grow by 22.05%. Given that Intelligent Bio Solutions, Inc. has higher upside potential than Standard BioTools, Inc., analysts believe Intelligent Bio Solutions, Inc. is more attractive than Standard BioTools, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INBSIntelligent Bio Solutions, Inc.0 0 0 LABStandard BioTools, Inc.1 2 0 -
Is INBS or LAB More Risky?
Intelligent Bio Solutions, Inc. has a beta of 4.455, which suggesting that the stock is 345.491% more volatile than S&P 500. In comparison Standard BioTools, Inc. has a beta of 1.264, suggesting its more volatile than the S&P 500 by 26.42%.
-
Which is a Better Dividend Stock INBS or LAB?
Intelligent Bio Solutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Standard BioTools, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intelligent Bio Solutions, Inc. pays -- of its earnings as a dividend. Standard BioTools, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INBS or LAB?
Intelligent Bio Solutions, Inc. quarterly revenues are $1.1M, which are smaller than Standard BioTools, Inc. quarterly revenues of $19.6M. Intelligent Bio Solutions, Inc.'s net income of -$3M is higher than Standard BioTools, Inc.'s net income of -$31.7M. Notably, Intelligent Bio Solutions, Inc.'s price-to-earnings ratio is -- while Standard BioTools, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intelligent Bio Solutions, Inc. is 21.27x versus 3.74x for Standard BioTools, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INBSIntelligent Bio Solutions, Inc.21.27x -- $1.1M -$3M LABStandard BioTools, Inc.3.74x -- $19.6M -$31.7M
-
Which has Higher Returns INBS or LNSR?
LENSAR, Inc. has a net margin of -269.38% compared to Intelligent Bio Solutions, Inc.'s net margin of -25.94%. Intelligent Bio Solutions, Inc.'s return on equity of -255.54% beat LENSAR, Inc.'s return on equity of -1013.45%.
Company Gross Margin Earnings Per Share Invested Capital INBSIntelligent Bio Solutions, Inc.19.33% -$0.35 $5.4M LNSRLENSAR, Inc.40.56% -$0.31 -$9.2M -
What do Analysts Say About INBS or LNSR?
Intelligent Bio Solutions, Inc. has a consensus price target of --, signalling upside risk potential of 1021.5%. On the other hand LENSAR, Inc. has an analysts' consensus of $15.00 which suggests that it could grow by 31%. Given that Intelligent Bio Solutions, Inc. has higher upside potential than LENSAR, Inc., analysts believe Intelligent Bio Solutions, Inc. is more attractive than LENSAR, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INBSIntelligent Bio Solutions, Inc.0 0 0 LNSRLENSAR, Inc.0 2 0 -
Is INBS or LNSR More Risky?
Intelligent Bio Solutions, Inc. has a beta of 4.455, which suggesting that the stock is 345.491% more volatile than S&P 500. In comparison LENSAR, Inc. has a beta of 0.695, suggesting its less volatile than the S&P 500 by 30.495%.
-
Which is a Better Dividend Stock INBS or LNSR?
Intelligent Bio Solutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENSAR, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intelligent Bio Solutions, Inc. pays -- of its earnings as a dividend. LENSAR, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INBS or LNSR?
Intelligent Bio Solutions, Inc. quarterly revenues are $1.1M, which are smaller than LENSAR, Inc. quarterly revenues of $14.3M. Intelligent Bio Solutions, Inc.'s net income of -$3M is higher than LENSAR, Inc.'s net income of -$3.7M. Notably, Intelligent Bio Solutions, Inc.'s price-to-earnings ratio is -- while LENSAR, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intelligent Bio Solutions, Inc. is 21.27x versus 2.29x for LENSAR, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INBSIntelligent Bio Solutions, Inc.21.27x -- $1.1M -$3M LNSRLENSAR, Inc.2.29x -- $14.3M -$3.7M
-
Which has Higher Returns INBS or MOVE?
Movano, Inc. has a net margin of -269.38% compared to Intelligent Bio Solutions, Inc.'s net margin of -5036.25%. Intelligent Bio Solutions, Inc.'s return on equity of -255.54% beat Movano, Inc.'s return on equity of -410.28%.
Company Gross Margin Earnings Per Share Invested Capital INBSIntelligent Bio Solutions, Inc.19.33% -$0.35 $5.4M MOVEMovano, Inc.-250% -$4.73 $1.5M -
What do Analysts Say About INBS or MOVE?
Intelligent Bio Solutions, Inc. has a consensus price target of --, signalling upside risk potential of 1021.5%. On the other hand Movano, Inc. has an analysts' consensus of $30.00 which suggests that it could grow by 3756.04%. Given that Movano, Inc. has higher upside potential than Intelligent Bio Solutions, Inc., analysts believe Movano, Inc. is more attractive than Intelligent Bio Solutions, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INBSIntelligent Bio Solutions, Inc.0 0 0 MOVEMovano, Inc.0 0 0 -
Is INBS or MOVE More Risky?
Intelligent Bio Solutions, Inc. has a beta of 4.455, which suggesting that the stock is 345.491% more volatile than S&P 500. In comparison Movano, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock INBS or MOVE?
Intelligent Bio Solutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Movano, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intelligent Bio Solutions, Inc. pays -- of its earnings as a dividend. Movano, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INBS or MOVE?
Intelligent Bio Solutions, Inc. quarterly revenues are $1.1M, which are larger than Movano, Inc. quarterly revenues of $80K. Intelligent Bio Solutions, Inc.'s net income of -$3M is higher than Movano, Inc.'s net income of -$4M. Notably, Intelligent Bio Solutions, Inc.'s price-to-earnings ratio is -- while Movano, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intelligent Bio Solutions, Inc. is 21.27x versus 11.77x for Movano, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INBSIntelligent Bio Solutions, Inc.21.27x -- $1.1M -$3M MOVEMovano, Inc.11.77x -- $80K -$4M
-
Which has Higher Returns INBS or NPCE?
NeuroPace, Inc. has a net margin of -269.38% compared to Intelligent Bio Solutions, Inc.'s net margin of -12.78%. Intelligent Bio Solutions, Inc.'s return on equity of -255.54% beat NeuroPace, Inc.'s return on equity of -149.8%.
Company Gross Margin Earnings Per Share Invested Capital INBSIntelligent Bio Solutions, Inc.19.33% -$0.35 $5.4M NPCENeuroPace, Inc.77.39% -$0.11 $89.7M -
What do Analysts Say About INBS or NPCE?
Intelligent Bio Solutions, Inc. has a consensus price target of --, signalling upside risk potential of 1021.5%. On the other hand NeuroPace, Inc. has an analysts' consensus of $19.25 which suggests that it could grow by 17.45%. Given that Intelligent Bio Solutions, Inc. has higher upside potential than NeuroPace, Inc., analysts believe Intelligent Bio Solutions, Inc. is more attractive than NeuroPace, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INBSIntelligent Bio Solutions, Inc.0 0 0 NPCENeuroPace, Inc.7 0 0 -
Is INBS or NPCE More Risky?
Intelligent Bio Solutions, Inc. has a beta of 4.455, which suggesting that the stock is 345.491% more volatile than S&P 500. In comparison NeuroPace, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock INBS or NPCE?
Intelligent Bio Solutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NeuroPace, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intelligent Bio Solutions, Inc. pays -- of its earnings as a dividend. NeuroPace, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INBS or NPCE?
Intelligent Bio Solutions, Inc. quarterly revenues are $1.1M, which are smaller than NeuroPace, Inc. quarterly revenues of $27.4M. Intelligent Bio Solutions, Inc.'s net income of -$3M is higher than NeuroPace, Inc.'s net income of -$3.5M. Notably, Intelligent Bio Solutions, Inc.'s price-to-earnings ratio is -- while NeuroPace, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intelligent Bio Solutions, Inc. is 21.27x versus 5.50x for NeuroPace, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INBSIntelligent Bio Solutions, Inc.21.27x -- $1.1M -$3M NPCENeuroPace, Inc.5.50x -- $27.4M -$3.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
69
RGC alert for Jan 7
Regencell Bioscience Holdings Ltd. [RGC] is up 58.95% over the past day.
Buy
69
WDC alert for Jan 7
Western Digital Corp. [WDC] is down 8.88% over the past day.
Buy
75
DRUG alert for Jan 7
Bright Minds Biosciences, Inc. [DRUG] is up 2.99% over the past day.
